Preclinical evaluation of an 131I-labeled benzamide for targeted radiotherapy of metastatic melanoma

Cancer Research

Volumn 70, Issue 10, 2010, Pages 4045-4053

  Joyal, John L ^a   Barrett, John A ^a   Marquis, John C ^a   Chen, Jianqing ^a   Hillier, Shawn M ^a   Maresca, Kevin P ^a   Boyd, Marie ^b   Gage, Kenneth ^c   Nimmagadda, Sridhar ^c   Kronauge, James F ^a   Friebe, Matthias ^d   Dinkelborg, Ludger ^d   Stubbs, James B ^e   Stabin, Michael G ^f   Mairs, Rob ^b   Pomper, Martin G ^c   Babich, John W ^a  

^a Lantheus Medical Imaging   (United States)

^b UNIVERSITY OF GLASGOW   (United Kingdom)

^c DEPARTMENT OF PATHOLOGY   (United States)

^d BAYER PHARMA AG   (Germany)

^e Radiation Dosimetry Services   (United States)

^f VANDERBILT UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BENZAMIDE DERIVATIVE; IODINE 131; MELANIN; MIP 1145; N (2 DIETHYLAMINOETHYL) 4 (4 FLUOROBENZAMIDO) 5 IODO 2 METHOXYBENZAMIDE I 131; UNCLASSIFIED DRUG; N (2 DIETHYLAMINOETHYL) 4 (4 FLUOROBENZAMIDO) 5 IODO 2 METHOXYBENZAMIDE; N-(2-DIETHYLAMINOETHYL)-4-(4-FLUOROBENZAMIDO)-5-IODO-2-METHOXYBENZAMIDE; RADIOACTIVE IODINE; RADIOPHARMACEUTICAL AGENT;

ANIMAL EXPERIMENT; ANIMAL MODEL; AREA UNDER THE CURVE; ARTICLE; CANCER CELL CULTURE; CONTROLLED STUDY; DOSE CALCULATION; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG PROTEIN BINDING; DRUG TUMOR LEVEL; DRUG UPTAKE; FEMALE; HUMAN; HUMAN CELL; MALE; MAXIMUM PLASMA CONCENTRATION; MELANOMA; MELANOMA CELL; METASTASIS; MONKEY; MOUSE; NONHUMAN; PRIORITY JOURNAL; SINGLE DRUG DOSE; TISSUE DISTRIBUTION; TUMOR XENOGRAFT; ANIMAL; DRUG SCREENING; EVALUATION; EXPERIMENTAL MELANOMA; MACACA; METABOLISM; NUDE MOUSE; PATHOLOGY; RADIATION DOSE; SCINTISCANNING; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; SURVIVAL RATE;

ANIMALS; BENZAMIDES; DRUG EVALUATION, PRECLINICAL; FEMALE; HUMANS; IODINE RADIOISOTOPES; MACACA FASCICULARIS; MALE; MELANINS; MELANOMA, EXPERIMENTAL; MICE; MICE, NUDE; NEOPLASM METASTASIS; RADIOPHARMACEUTICALS; RADIOTHERAPY DOSAGE; SURVIVAL RATE; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 77952844046     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-09-4414     Document Type: Article

References (50)

1. Eggermont AM, Kirkwood JM. Re-evaluating the role of dacarbazine in metastatic melanoma: what have we learned in 30 years? Eur J Cancer 2004;40:1825-1836
2. Atkins MB, Lotze MT, Dutcher JP, et al. High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993. J Clin Oncol 1999;17: 2105-2116
3. Sertoli M.R. Bernengo M.G. Ardizzoni A. Brunetti I. Falcone A. Vidili M.G. Cusimano M.P. Appino A. Doveil G. Fortini C. Rosso R. Phase II trial of recombinant alpha-2b interferon in the treatment of metastatic skin melanoma Oncology 1989 46 2 96-98 3. Sertoli MR, Bernengo MG, Ardizzoni A, et al. Phase II trial of recombinant α-2b interferon in the treatment of metastatic skin melanoma. Oncology 1989;46:96-98 (Pubitemid 19075320)
4. Atallah E, Flaherty L. Treatment of metastatic malignant melanoma. Curr Treat Options Oncol 2005;6:185-193
5. Tarhini AA, Agarwala SS. Cutaneous melanoma: available therapy for metastatic disease. Dermatol Ther 2006;19:19-25.
6. Tarhini AA, Agarwala SS. Interleukin-2 for the treatment of melanoma. Curr Opin Investig Drugs 2005;6:1234-1239
7. Tarhini A.A. Agarwala S.S. Novel agents in development for the treatment of melanoma Expert Opinion on Investigational Drugs 2005 14 7 885-892 DOI 10.1517/13543784.14.7.885 7. Tarhini AA, Agarwala SS. Novel agents in development for the treatment of melanoma. Expert Opin Investig Drugs 2005;14:885-892 (Pubitemid 41030955)
8. Gualandri L, Betti R, Crosti C. Clinical features of 36 cases of amelanotic melanomas and considerations about the relationship between histologic subtypes and diagnostic delay. J Eur Acad Dermatol 2009;23:283-287
9. Tolleson WH. Human melanocyte biology, toxicology, and pathology. J Environ Sci Health C 2005;23:105-161
10. Sulaimon SS, Kitchell BE. The biology of melanocytes. Vet Dermatol 2003;14:57-65.
11. Prota G. Melanins, melanogenesis and melanocytes: Looking at their functional significance from the chemist's viewpoint Pigment Cell Research 2000 13 4 283-293 DOI 10.1034/j.1600-0749.2000.130412.x 11. Prota G. Melanins, melanogenesis and melanocytes: looking at their functional significance from the chemist's viewpoint. Pigment Cell Res 2000;13:283-293 (Pubitemid 30610807)
12. Larson BS. Interaction between chemicals and melanin. Pigment Cell Res 1993;6:127-133
13. Knorle R. Schniz E. Feuerstein T.J. Drug accumulation in melanin: An affinity chromatographic study Journal of Chromatography B: Biomedical Applications 1998 714 2 171-179 DOI 10.1016/S0378-4347(98)00242-4, PII S0378434798002424 13. Knorle R, Schniz E, Feuerstein TJ. Drug accumulation in melanin: an affinity chromatography study. J Chromatogr B Biomed Sci Appl 1998;714:171-179 (Pubitemid 28386839)
14. Bridelli M.G. Ciati A. Crippa P.R. Binding of chemicals to melanins re-examined: Adsorption of some drugs to the surface of melanin particles Biophysical Chemistry 2006 119 2 137-145 DOI 10.1016/j.bpc.2005.06.004, PII S0301462205001298 14. Birdelli MG, Ciati A, Crippa PR. Binding of chemicals to melanins re-examined: Adsorption of some drugs to the surface of melanin particles. Biophys Chem 2006;119:137-145 (Pubitemid 43105450)
15. Land EJ, Ramsden CA, Riley PA. Toxicological aspects of melanin and melanogenesis. In: Nordlund JJ, Boissy RE, Hearing VJ, King RA, Oetting WS, Ortonne J, editors. The pigmentary system: physiology and pathophysiology. 2nd ed. Oxford: Blackwell Publishing Ltd.; 2006.
16. Brandau W. Niehoff T. Pulawski P. Jonas M. Dutschka K. Sciuk J. Coenen H.H. Schober O. Structure distribution relationship of iodine-123-iodobenzamides as tracers for the detection of melanotic melanoma Journal of Nuclear Medicine 1996 37 11 1865-1871 16. Brandau W, Niehoff T, Pulawski P, et al. Structure distribution relationship of iodine-123-iodobenzamides as tracers for the detection of melanotic melanoma. J Nucl Med 1996;37:1865-1871 (Pubitemid 26378685)
17. Larisch R. Schulte K.-W. Vosberg H. Ruzicka T. Muller-Gartner H.-W. Differential accumulation of iodine-123-iodobenzamide in melanotic and amelanotic melanoma metastases in vivo Journal of Nuclear Medicine 1998 39 6 996-1001 17. Larisch R, Schulte K, Vosberg H, et al. Differential accumulation of iodine-123-iodobenzamide in melanotic and amelanotic melanoma metastases in vivo. J Nucl Med 1998;39:996-1001. (Pubitemid 28270114)
18. Eisenhut M, Hull WE, Mohammed A, et al. Radioiodinated N- (2-diethylaminoethyl)benzamide derivatives with high melanoma uptake: structure-affinity relationships, metabolic fate, and intracellular localization. J Med Chem 2000;43:3913-3922
19. Labarre P. Papon J. Moreau M.-F. Moins N. Bayle M. Veyre A. Madelmont J.-C. Melanin affinity of N-(2-diethylaminoethyl)-4-iodobenzamide, an effective melanoma imaging agent Melanoma Research 2002 12 2 115-121 DOI 10.1097/00008390-200204000-00003 19. Labarre P, Papon J, Moreau MF, et al. Melanin affinity of N-(2-diethylaminoethyl)- 4-iodobenzamide, an effective melanoma imaging agent. Melanoma Res 2002;12:115-121 (Pubitemid 34478451)
20. 2), an imaging agent for melanoma staging: Relation to pigmentation Nuclear Medicine and Biology 2005 32 5 451-458 DOI 10.1016/j.nucmedbio.2005.04.006, PII S0969805105001010 20. Mansard S, Papon J, Moreau MF, et al. Uptake in melanoma cells of N-(2- diethylaminoethyl)-2-iodobenzamide (BZA2), an imaging agent for melanoma staging: relation to pigmentation. Nucl Med Biol 2005; 32:451-458 (Pubitemid 40854096)
21. Pham T.Q. Greguric I. Liu X. Berghofer P. Ballantyne P. Chapman J. Mattner F. Dikic B. Jackson T. Loc'h C. Katsifis A. Synthesis and evaluation of novel radioiodinated benzamides for malignant melanoma Journal of Medicinal Chemistry 2007 50 15 3561-3572 DOI 10.1021/jm0701627 21. Pham TQ, Greguric I, Liu X, et al. Synthesis and evaluation of novel radioiodinated benzamides for malignant melanoma. J Med Chem 2007;50:3561-3572 (Pubitemid 47195463)
22. Morton DB, Griffiths PHM. Endpoints in animal study protocols. Vet Rec 1985;116:43143.
23. Stabin M.G. Sparks R.B. Crowe E. OLINDA/EXM: The second-generation personal computer software for internal dose assessment in nuclear medicine Journal of Nuclear Medicine 2005 46 6 1023-1027 23. Stabin MG, Sparks RB, Crowe E. OLINDA/EXM: the second-generation personal computer software for internal dose assessment in nuclear medicine. J Nucl Med 2005;46:1023-1027 (Pubitemid 43733519)
24. 131I] labeled iodoquinoxaline derivative for an effective melanoma treatment. J Canc Sci Ther 2009;1:1-7.
25. Joyal JL, Hillier SM, Marquis JC, et al. Molecular targeting of melanoma with radiolabeled benzamides. J Nucl Med 2008;49:16P.
26. Michelot JM, Moreau MFC, Labarre PG, et al. Synthesis and evaluation of new iodine-125 radiopharmaceuticals as potential tracers for malignant melanoma. J Nucl Med 1991;32:1573-1580
27. Nicholl C, Mohammed A, Hull WE, Bubeck B, Eisenhut M. Pharmacokinetics of iodine-123-IMBA for melanoma imaging. J Nucl Med 1997;38:127-133
28. Michelot JM, Moreau MFC, Veyre AJ, et al. Phase II scintigraphic clinical trial of malignant melanoma and metastases with iodine- 123-N(2- diethylaminoethyl 4-iodobenzamide). J Nucl Med 1993;34: 1260-1266
29. Emami B, Lyman J, Brown A, et al. Tolerance of normal tissue to therapeutic irradiation. Int J Radiat Oncol Biol Phys 1991;21:109-122
30. 131I]MIBG and topotecan: a rationale for combination therapy for neuroblastoma. Cancer Lett 2005;228:221-227
31. 131I]Meta- iodobenzylguanidine and topotecan combination treatment of tumours expressing the noradrenaline transporter. Clin Cancer Res 2005;11:7929-7937
32. 131I-meta-iodobenzylguanidine with topotecan as a radiosensitiser in children with metastatic neuroblastoma. Cancer Biother Radiopharm 2005;20:195-199
33. Mairs RJ, Boyd M. Optimizing MIBG therapy of NETs - preclinical evidence of dose maximization and synergy. Nucl Med Biol 2008; 35:S9-20.
34. Gidanian S. Mentelle M. Meyskens F.L. Jr. Farmer P.J. Melanosomal damage in normal human melanocytes induced by UVB and metal uptake - A basis for the pro-oxidant state of melanoma Photochemistry and Photobiology 2008 84 3 556-564 DOI 10.1111/j.1751-1097.2008.00309.x 34. Gidanian S, Mentelle M, Meyskens FL, Farmer PJ. Melanosomal damage in normal human melanocytes induced by UVB and metal uptake - a basis for the pro-oxidant state of melanoma. Photochem Photobiol 2008;84:556-564 (Pubitemid 351589373)
35. Wittgen H.G.M. Van Kempen L.C.L.T. Reactive oxygen species in melanoma and its therapeutic implications Melanoma Research 2007 17 6 400-409 DOI 10.1097/CMR.0b013e3282f1d312, PII 0000839020071200000010 35. Wittgen HG, van Kempen LC. Reactive oxygen species in melanoma and its therapeutic implications. Melanoma Res 2007;17:400-409 (Pubitemid 350084996)
36. Smit N.P.M. Van Nieuwpoort F.A. Marrot L. Out C. Poorthuis B. Van Pelt H. Meunier J.-R. Pavel S. Increased melanogenesis is a risk factor for oxidative DNA damage - Study on cultured melanocytes and atypical nevus cells Photochemistry and Photobiology 2008 84 3 550-555 DOI 10.1111/j.1751-1097.2007. 00242.x 36. Smit NP, van Nieuwpoort FA, Marrot L, et al. Increased melanogenesis is a risk factor for oxidative DNA damage - study on cultured melanocytes and atypical nevus cells. Photochem Photobiol 2008; 84:550-555 (Pubitemid 351589354)
37. Fruehauf JP, Trapp V. Reactive oxygen species: an Achilles' heel of melanoma? Expert Rev Anticancer 2008;8:1751-1757
38. Fruehauf JP, Meyskens FL. Reactive oxygen species: a breath of life or death? Clin Cancer Res 2007;13:789-794
39. Kirshner JR, He S, Balasubramanyam V, et al. Elesclomol induces cancer cell apoptosis through oxidative stress. Mol Cancer Ther 2008;7:2319-2327
40. Barranco SC, Romsdahl MM, Humphrey RM. The radiation response of human malignant melanoma cells grown in vitro. Cancer Res 1971;31:830-833
41. Einar R. Radiation sensitivity in vitro of primary tumors and metastatic lesions of malignant melanoma. Cancer Res 1992;52:4453-4457
42. Rofstad EK. Radiation biology of malignant melanoma. Acta Radiol Oncol 1986;25:1-10.
43. Olivier KR, Schild SE, Morris CG, Brown PD, Markovic SN. A higher radiotherapy dose is associated with more durable palliation and longer survival in patients with metastatic melanoma. Cancer 2007;110: 1791-1795
44. Berk LB. Radiation therapy as primary and adjuvant treatment for local and regional melanoma. Cancer Control 2008;15:233-238
45. McWilliams RR, Brown PD, Buckern JC, et al. Treatment of brain metastases from melanoma. Mayo Clin Proc 2003;78:1529-1536
46. Wolf M. Eskerski H. Bauder-Wust U. Haberkorn U. Eisenhut M. Alkylating benzamides with melanoma cytotoxicity: Experimental chemotherapy in a mouse melanoma model Melanoma Research 2006 16 6 487-496 DOI 10.1097/01.cmr. 0000232294.14408.6a, PII 0000839020061200000003 46. Wolf M, Eskerski H, Bauder-Wust U, Haberkorn U, Eisenhut M. Alkylating benzamides with melanoma cytotoxicity: experimental chemotherapy in mouse melanoma model. Melanoma Res 2006; 16:487-496 (Pubitemid 44934706)
47. Desbois N, Gardette M, Papon J, et al. Design, synthesis and preliminary biological evaluation of acridine compounds as potential agents for a combined targeted chemo-radionuclide therapy approach to melanoma. Bioorg Med Chem 2008;16:7671-7690
48. Miao Y, Owen NK, Fischer DR, et al. Therapeutic efficacy of a (188) Re-labeled α-melanocyte-stimulating hormone peptide analog in murine and human melanoma-bearing mouse models. J Nucl Med 2005;46:121-129
49. Dadachova E. Nosanchuk J.D. Shi L. Schweitzer A.D. Frenkel A. Nosanchuk J.S. Casadevall A. Dead cells in melanoma tumors provide abundant antigen for targeted delivery of ionizing radiation by a mAb to melanin Proceedings of the National Academy of Sciences of the United States of America 2004 101 41 14865-14870 DOI 10.1073/pnas.0406180101 49. Dadachova E, Nosanchuk JD, Shi L, et al. Dead cells in melanoma tumors provide abundant antigen for targeted delivery of ionizing radiation by a mAb to melanin. P Natl Acad Sci U S A 2004;101: 14865-14870 (Pubitemid 39410766)
50. Dadachova E, Revskaya E, Sesay MA, et al. Pre-clinical evaluation and efficacy studies of a melanin-binding IgM antibody labeled with (188)Re against experimental human metastatic melanoma in nude mice. Cancer Biol Ther 2008;7:1116-1127